ABBOTT RECEIVES FDA CLEARANCE FOR ASSERT-IQ INSERTABLE CARDIAC MONITOR

Abbott announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats. This clearance builds on Abbott's portfolio of connected health devices that can better help doctors manage and treat their patients remotely.

Irregular heartbeats – known as arrhythmias – may be fleeting, making diagnosis challenging in many patients. ICMs – small devices with sensors inserted just under the skin of the chest – are designed to provide constant, real-time monitoring of a person's heart to detect and identify arrhythmias that can lead to symptoms such as fainting, irregular pulse and shortness of breath.

While many commercially available ICMs monitor a person's heart rhythms for a few years, Assert-IQ offers two options with a battery life of at least three or six years to provide doctors with a new level of flexibility in diagnostic monitoring. While the three-year option may be preferred for more traditional monitoring, such as diagnosing fainting, heart palpitations or detections of abnormal heart rhythms, an option offering at least six years of battery life empowers physicians to monitor long-term. This monitoring can be especially important when caring for people who are undergoing therapy, have recently had a cardiac ablation procedure or are at risk of developing further arrhythmias such as atrial fibrillation. In both options, advanced algorithms are available to detect irregular heartbeats and provide clinically actionable data.

Using Bluetooth^® technology, Abbott's Assert-IQ ICM is designed to remain connected to a transmitter – usually the person's own cell phone – where it checks heart rhythms every 20 seconds, transmitting results in real-time to the clinic's portal. Additionally, some models of the Assert-IQ ICM family can be remotely programmed allowing the clinician to adjust the settings of the connected device, optimize performance and limit unnecessary alerts or transmissions – all without requiring the patient to visit the clinic.

The Assert-IQ ICM also offers advanced diagnostic capabilities to provide physicians with more clinically relevant information about the cardiovascular health of the patient, allowing care providers to make clinical decisions faster.